Home > Neurology > ECTRIMS 2021 > Treatment Trials and Strategies > Dynamic scoring system aids decision to switch MS therapies early

Dynamic scoring system aids decision to switch MS therapies early

Presented By
Dr Camille Sabathé, French Institute of Health and Medical Research, France
Conference
ECTRIMS 2021
A newly developed dynamic scoring system has been developed and validated to support the decision of switching at an early stage from first-line to second-line MS therapies. Based on 5-year relapse-free survival, it was concluded that at least one-third of relapsing-remitting MS (RRMS) patients might benefit from an earlier switch [1]. Early identification of suboptimal response could prevent irreversible disability progression by timely switching from a first-line to a more potent second-line disease-modifying therapy (DMT) [2]. With this in mind, Dr Camille Sabathé (French Institute of Health and Medical Research, France) and colleagues developed a dynamic scoring system to aid the early decision of switching therapies. They had at their disposal a French cohort of 12,823 adult RRMS patients who had started a first-line treatment between 2008 and 2018. Patients who switched to a second-line treatment because of inefficacy were compared with patients rema...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on